US 12,486,294 B2
Radioisotope labeled compound for imaging or treatment of prostate cancer
Jae Min Jeong, Seoul (KR); Nadeem Ahmed Lodhi, Seoul (KR); and Yun-sang Lee, Seoul (KR)
Assigned to Seoul National University R&DB Foundation, Seoul (KR)
Appl. No. 17/770,315
Filed by SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
PCT Filed Oct. 22, 2020, PCT No. PCT/KR2020/014501
§ 371(c)(1), (2) Date Apr. 20, 2022,
PCT Pub. No. WO2021/080352, PCT Pub. Date Apr. 29, 2021.
Claims priority of application No. 10-2019-0132984 (KR), filed on Oct. 24, 2019.
Prior Publication US 2022/0402951 A1, Dec. 22, 2022
Int. Cl. C07F 13/00 (2006.01); C07B 59/00 (2006.01)
CPC C07F 13/005 (2013.01) [C07B 59/004 (2013.01); A61K 2121/00 (2013.01); A61K 2123/00 (2013.01); C07B 2200/05 (2013.01)] 14 Claims
 
1. A compound represented below or a pharmaceutically acceptable salt by formula 1 thereof:

OG Complex Work Unit Chemistry
wherein L is a linker.